FDA clears 2 new HCV drugs

The market for hepatitis C drugs has been closely followed as new — and expensive — treatments have resulted in high cure rates. Now, two additional oral HCV drugs have received FDA approval, according to a Medscape report.

Technivie, from AbbVie, is a combination of ombitasvir, paritaprevir and ritonavir. The drug is designed for use with ribavarin for adult HCV patients with genotype 4, according to the report. All patients who used Technivie with ribavarin experienced sustained virologic response at 12 weeks, compared to 91 percent of patients who used the drug without ribavarin, according to the report.

Daklinza, from Bristol-Myers Squibb, also received FDA approval. The drug was cleared for use with Sovaldi from Gilead Sciences for the treatment of HCV genotype 3, according to the report. Sustained virologic response at 12-weeks was achieved by 98 percent of patients with no cirrhosis and in 58 percent of patients with cirrhosis.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast